Join us in person or virtually for this Master Class symposium at ASCO GU 2026 where experts will facilitate small group discussions and case reviews to provide insights on optimizing genetic testing, individualizing treatment strategies with PARP inhibitors, monitoring/managing treatment-related adverse events, and understanding the latest relevant emerging data presented at the meeting.

It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.

It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.

Learn about the results of recent trials, updates to NCCN Guideline recommendations, and common supportive care needs, so that you can provide optimal management for patients with metastatic prostate cancer.

Learn about the results of recent trials, updates to NCCN Guideline recommendations, and common supportive care needs, so that you can provide optimal management for patients with metastatic prostate cancer.

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with metastatic castration-resistant prostate cancer.

These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.